StockData

Autolus Therapeutics vs Century Therapeutics

AUTL and IPSC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AUTL and IPSC compare

Autolus Therapeutics is the larger company, worth 1.2 times as much as Century Therapeutics ($290M against $248M).

Century Therapeutics scores higher on the StockData Score (8 against 5 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAUTLIPSC
Size and price
Market cap$290M$248M
Share price$1.09$1.37
Change, 1 year−20.4%190%
Change, 5 years−82.6%−92.0%
Beta (5Y)3.472.19
Employees75478
StockData Score
Total score58 (better)
Valuation score11
Growth score3 (better)1
Performance score01 (better)
Health score15 (better)
Dividend score00
Valuation
P/S2.5×–
P/B3.9×1.1× (better)
FCF yield−80.2%−35.5% (better)
Fair value$1.36–
Margin of safety19.8%–
Growth
Revenue growth (TTM)292%–
Profitability
Gross margin15.7%–
Operating margin−211%–
Net margin−239%–
FCF margin−198%–
Return on equity−133%−49.7% (better)
Return on invested capital–−113%
Financial health
Debt / equity–0.00
Interest coverage−5.9×–
Current ratio4.898.28 (better)
Altman Z-score−4.60−2.30 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield–−0.24%
Shareholder yield0.00% (better)−0.24%
Ownership
Held by institutions49.7%87.3%
Held by insiders24.6%3.8%
Insider net buying, 12 months−$15.7K$10.6K (better)
Short interest, % of float–18.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.